Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
The Covid vaccine battleground gets younger
The FDA has finally confirmed the date of a review of Covid vaccine data in the very young, but has Pfizer/Biontech already won the race?
Covid drives a record jump in research spending for big pharma
A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.
A bad day for Molecular Partners
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
